United Therapeutics price target raised to $575 from $510 at Oppenheimer

Oppenheimer raised the firm’s price target on United Therapeutics (UTHR) to $575 from $510 and keeps an Outperform rating on the shares. Following positive results from TETON-2 on September 2, the firm sees a clear path for TYVASO in IPF to generate sales of $5.4B by 2033. Results were in-line with Oppenheimer’s base case scenario of TYVASO achieving statistically significant benefit in FVC supported by significant improvements in key secondary endpoints. While investors await the full results at the upcoming ERS Congress, the magnitude of benefit suggests that TYVASO has an impact not just in patients with underlying PH, positioning it as a potential backbone therapy. The data also positively read through to TETON-1 expected in the first half of 2026 given the similar trial design and baseline characteristics, the firm adds.